GLP-1 Therapies and the Syndemic in Indian Country: Clinical Outcomes, Emerging Applications, and Access | October 27, 2026
Date of Presentation: October 27, 2026
Type: Past Presentation
Audience: Clinical
Program: General Session
Keywords: #GIP #GLP-1 #incretin #medication access #metabolic #substance use disorders
In this presentation, Dr. Hannah Wenger, and Dr. Nicholas Duca compare the burden of obesity and related metabolic disease among American Indian and Alaska Native populations with the broader US population, explain the pharmacology and patient-centered outcomes of GLP-1 receptor agonists and dual GIP/GLP-1 agonists, describe the relevance of incretin-based therapies to substance use disorders and syndemic care and review medication access across public and private insurances as well as IHS and other federal health entities.
Presented by:
Nicholas S. Duca
MD
Nicholas S. Duca, MD, is an Associate Professor of Medicine at Penn State College of Medicine and a general internist at Penn State Health Milton S. Hershey Medical Center. He is board certified in both Internal Medicine and Obesity Medicine, with clinical and academic interests spanning obesity and metabolic health, primary care, gender-affirming care, and medical education.
Hannah C. Wenger
MD
Hannah C. Wenger, MD (she) is an Associate Physician in the Division of General Internal Medicine at Massachusetts General Hospital (MGH) and an Instructor in Medicine at Harvard Medical School. She is also a partner at The Raven Collective, an Indigenous- and female-owned tribal health consulting firm in the United States. Hannah is a national expert in Indigenous health and medical care for transgender individuals.
Resources Provided:
Date added: August 30, 2026



















































































